<SEC-DOCUMENT>0001193125-25-313008.txt : 20251210
<SEC-HEADER>0001193125-25-313008.hdr.sgml : 20251210
<ACCEPTANCE-DATETIME>20251209173644
ACCESSION NUMBER:		0001193125-25-313008
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20251210
DATE AS OF CHANGE:		20251209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STAAR SURGICAL CO
		CENTRAL INDEX KEY:			0000718937
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				953797439
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1227

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-11634
		FILM NUMBER:		251560128

	BUSINESS ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		6263037902

	MAIL ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STAAR SURGICAL COMPANY
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d57431ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549</B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROXY
STATEMENT PURSUANT TO SECTION 14(A) OF THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the Registrant&#8194;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other
than the Registrant&nbsp;&#9744; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT> </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material under <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>STAAR SURGICAL COMPANY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules
<FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>On December&nbsp;9, 2025, the Chief Executive Officer of STAAR Surgical Company (&#8220;STAAR&#8221; or
the &#8220;Company&#8221;) sent the following email to STAAR employees: </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Update on Alcon Merger </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To: All Employees of STAAR </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Team, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I&#8217;m writing to provide an update regarding our proposed merger with Alcon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Earlier today, STAAR and Alcon announced an amendment to the previously announced merger agreement. Alcon has agreed to a price &#8220;bump&#8221;, and the
amendment to the merger agreement increases the aggregate consideration paid for each share of STAAR common stock to <B>$30.75/share</B>, an increase of $2.75/share from the prior merger agreement. This is another clear sign that Alcon believes
strongly in STAAR, its employees and our bright future. The $30.75 price represents a ~66% premium to the closing price of STAAR common stock on August&nbsp;4, 2025 and ~10% premium to $28/share. Alcon&#8217;s offer remains 100% cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As you may know, the Alcon merger transaction is contested, and shareholders had expressed objections to the $28/share merger price and other terms and
conditions of the merger. The amendment increases the merger price, and is intended to address other shareholder objections, including management compensation. Among other things, the amendment modifies the approach to RSUs and PSUs, which is
discussed in the updated FAQ regarding employee compensation and benefits (link). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendment announced today does not change the timing of the Special
Meeting of Stockholders, which is scheduled for Friday, December 19. The record date for the Special Meeting remains the close of business on October&nbsp;24, 2025. Stockholders who hold shares as of the record date will be eligible to vote at the
Special Meeting on December&nbsp;19, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I am proud of each of you, as you have done a great job of staying focused on the business despite the noise
that has surrounded STAAR in the last several months. You have continued to advance the business, improve our operations and deliver against objectives and I am very grateful for your contributions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no changes to our go forward approach as a result of this new amendment to the merger agreement. Prior to the closing of the merger, we will
continue to operate business as usual. As we have discussed in the past, I would ask for you to help by remaining focused on your responsibilities to advance the important work underway across the Company to impact as many customers and patients as
possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On behalf of the STAAR Board of Directors and management team, thank you for your continued dedication to STAAR and our mission. We have much
to be thankful for, and I wish you and your families a happy and healthy holiday season. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g57431g1210025455923.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stephen C. Farrell </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g57431g1210025456111.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Also on December&nbsp;9, 2025, the Company updated its Employee Q&amp;A regarding compensation and
benefits to STAAR employees with the following new and updated FAQs: </I></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What will happen to the shares of STAAR common stock that I own upon the closing of the merger? [updated
December&nbsp;9, 2025] </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Upon the closing of the merger, your shares of STAAR common stock will convert into the right to receive $30.75
per share in cash, without interest. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Promptly following the closing of the merger, you will receive instructions as to how to surrender your shares of
STAAR common stock to STAAR&#8217;s exchange agent, which will be responsible for making payments to STAAR shareholders. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What will happen to my STAAR stock options? [updated December&nbsp;9, 2025] </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">In-the-money</FONT></FONT> options</B>: Upon
the closing of the merger, any unvested options will automatically vest and you will become entitled to a cash payment for each share underlying your unvested options and vested options that you have not exercised that are <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#8220;in-the-money</FONT></FONT> options&#8221; (<I>i.e.,</I> options with an exercise price of less than $30.75 per share), in an amount equal to the excess of $30.75 over the applicable
per share exercise price, without interest and less applicable tax withholding. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Example:</I> If you hold options to purchase 500 shares of STAAR common stock (whether unvested or vested and
not yet exercised) with an exercise price of $18.75, you would be entitled to receive $6,000 (<I>i.e.,</I> 500 shares multiplied by the difference of $30.75 -$18.75 =$12), less applicable tax withholding. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
<P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-the-money</FONT></FONT></FONT>
options</B>: Upon the closing of the merger, any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-the-money</FONT></FONT></FONT> options (<I>i.e.</I>, options with an exercise price of $30.75
or more) will be cancelled and no payment will be made. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What will happen to my STAAR restricted stock units (RSUs)? [updated December&nbsp;9, 2025]
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Upon the closing of the merger, any STAAR RSUs you hold (regardless of whether granted before August&nbsp;4,
2025) will generally be converted into Alcon RSUs covering a number of Alcon shares of equivalent value calculated based on the merger consideration of $30.75 per share and otherwise subject to the same terms and conditions as apply to your STAAR
RSUs immediately before the closing. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>After my STAAR RSUs are converted into Alcon RSUs, will they have the same vesting terms? [added
December&nbsp;9, 2025] </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">STAAR RSUS that are converted into Alcon RSUs will maintain their existing vesting terms. For example, if you
have a STAAR RSU that is subject to vesting as to 1/3 on each of March&nbsp;14, 2026, 2027 and 2028, any tranches that are scheduled to vest after the closing of the merger will continue to vest on their original vesting date (but will be settled in
Alcon shares upon vesting). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">STAAR RSUs granted before August&nbsp;4, 2025, also have the benefit of a
<FONT STYLE="white-space:nowrap">so-called</FONT> &#8220;double-trigger&#8221; vesting provision under the terms of the STAAR equity plan, which provide that, following the closing of the Alcon merger, the Alcon RSUs received upon conversion of
STAAR RSUs will be accelerated and vest in full if the award holder&#8217;s employment is involuntarily terminated within 12 months following the closing (i)&nbsp;for &#8220;good reason&#8221; by the award holder or (ii)&nbsp;by the Company other
than for &#8220;cause&#8221;. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What will happen to my STAAR performance stock units (PSUs)? [updated December&nbsp;9, 2025]
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Upon the closing of the merger, your STAAR PSUs will generally be converted into Alcon RSUs covering a number of
Alcon shares of equivalent value (with performance deemed achieved at 100% of target and the PSUs earned as of the closing of the merger) calculated based on the merger consideration of $30.75 per share and otherwise subject to the same terms and
conditions as apply to your STAAR PSUs immediately before the closing (except that performance conditions will no longer apply). </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>After my STAAR PSUs are converted into Alcon RSUs, will they have the same vesting terms? [added
December&nbsp;9, 2025] </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Since STAAR PSUs are being converted into Alcon RSUs, the performance conditions applicable to the STAAR PSUs are
being eliminated, which impacts vesting. The STAAR PSUs were granted with performance conditions, pursuant to which the PSUs could be earned in up to five tranches through December 2027. Vesting varied based on when the performance conditions were
satisfied for each tranche; once performance was satisfied for a tranche, half of the earned PSUs would vest, with half vesting on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of such date. As performance is being deemed achieved
at 100% of target, the STAAR PSUs that are converted into Alcon RSUs will no longer be subject to the variable vesting of the original PSUs. Instead, these awards will be subject to vesting as to 50% on the 15<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP> day of the second month following the quarter in which the closing occurs, with the remaining 50% vesting on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of such date.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">STAAR PSUs will also have the benefit of a <FONT STYLE="white-space:nowrap">so-called</FONT>
&#8220;double-trigger&#8221; vesting provision under the terms of the STAAR equity plan, which provide that, following the closing of the Alcon merger, the Alcon RSUs received upon conversion of the STAAR PSUs will be accelerated and vest in full if
the award holder&#8217;s employment is involuntarily terminated within 12 months following the closing (i)&nbsp;for &#8220;good reason&#8221; by the award holder or (ii)&nbsp;by the Company other than for &#8220;cause&#8221;. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The questions and answers above are provided as a general summary and are based on the terms of the
merger agreement governing the merger of STAAR Surgical Company (&#8220;STAAR&#8221;) and Alcon Inc. (&#8220;Alcon&#8221;). In the event of any conflict with the information in this Q&amp;A, the terms and conditions of the merger agreement and all
applicable plan documents, agreements, policies and programs will govern. Nothing contained in this Q&amp;A should be construed to constitute legal or tax advice. STAAR (and its successors) reserves the right to amend, change or terminate any of its
compensation and benefit plans, programs or policies in accordance with their terms at any time and in its discretion. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Information About the Merger and Where to Find It </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication relates to the proposed transaction involving the Company. In connection with the proposed transaction, the Company has filed relevant
materials with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), including the Company&#8217;s definitive proxy statement on Schedule 14A (the &#8220;Proxy Statement&#8221;), on September&nbsp;16, 2025. The Proxy Statement was
first sent to Company stockholders on September&nbsp;16, 2025 and was thereafter supplemented. This communication is not a substitute for the Proxy Statement or any other document that the Company may file with the SEC or send to its stockholders in
connection with the proposed transaction. BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, INCLUDING THE PROXY STATEMENT, AS WELL AS ANY AMENDMENTS OR
SUPPLEMENTS THERETO, IN CONNECTION WITH THE PROPOSED TRANSACTION WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain the documents (when
available) free of charge at the SEC&#8217;s website, www.sec.gov, or by visiting the Company&#8217;s investor relations website, https://investors.staar.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Offer or Solicitation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication is for
informational purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any
securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participants in the Solicitation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under SEC rules,
the Company and certain of its directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from the holders of the Company&#8217;s common stock in connection with the
proposed transaction. Information about the directors and executive officers of the Company and their ownership of the Company&#8217;s common stock is set forth in the Proxy Statement, the definitive proxy statement for the Company&#8217;s 2025
Annual Meeting of Stockholders (the &#8220;Annual Proxy Statement&#8221;), which was filed with the SEC on April&nbsp;24, 2025 (and which is available at
https://www.sec.gov/ix?doc=/Archives/edgar/data/0000718937/000095017025058174/staa-0250424.htm), including the sections captioned &#8220;Compensation of Directors,&#8221; &#8220;Information Regarding Executive Officers&#8221; and &#8220;Security
Ownership of Principal Shareholders and Management,&#8221; or its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;27, 2024, which was filed with the SEC on February&nbsp;21, 2025 (and which is
available at https://www.sec.gov/ix?doc=/Archives/edgar/data/0000718937/000095017025024813/staa-20241227.htm), and in other documents filed by the Company with the SEC. To the extent holdings of such participants in the Company&#8217;s securities
have changed since the amounts described in the Proxy Statement, such changes have been reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC by the Company&#8217;s
directors and executive officers. These documents can be obtained free of charge from the sources indicated above. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests,
by security holdings or otherwise, will be contained in other relevant materials to be filed with the SEC in respect of the proposed transaction when they become available. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information covered by this communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements often contain words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;will,&#8221;
&#8220;should,&#8221; &#8220;may,&#8221; and similar terms. All statements in this communication that are not statements of historical fact are forward-looking statements. These forward-looking statements are neither promises nor guarantees and
involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from what is expressed or implied by the forward-looking statements, including, but not
limited to: (1)&nbsp;the occurrence of any event, change or other circumstances that could give rise to the termination of the Alcon merger agreement or could cause the consummation of the proposed transaction to be delayed or to fail to occur;
(2)&nbsp;the failure to obtain approval of the proposed transaction from the Company&#8217;s stockholders; (3)&nbsp;the failure to obtain certain required regulatory approvals or the failure to satisfy any of the other closing conditions to the
completion of the proposed transaction within the expected timeframes or at all; (4)&nbsp;risks related to disruption of management&#8217;s attention from the Company&#8217;s ongoing business operations due to the proposed transaction; (5)&nbsp;the
effect of the announcement of the proposed transaction on the ability of the Company to retain and hire key personnel and maintain relationships with its customers, suppliers and others with whom it does business, or on its operating results and
business generally; (6)&nbsp;the ability of the Company to meet expectations regarding the timing and completion of the transaction; (7)&nbsp;the outcome of any legal proceedings that may be instituted against the Company related to the proposed
transaction; (8)&nbsp;the possibility that the Company&#8217;s stock price may decline significantly if the proposed transaction is not consummated; and (9)&nbsp;other important factors set forth in the Proxy Statement under the caption &#8220;Risk
Factors&#8221; and the Company&#8217;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;27, 2024 under the caption &#8220;Risk Factors,&#8221; as any such factors may be updated from time to time in
the Company&#8217;s other filings with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-looking statements speak only as of the date they are made and, except as may be required under
applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g57431g1210025455923.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g57431g1210025455923.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !( ' # 2(  A$! Q$!_\0
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M>?EQ^9% 'KMYJ=EI\32WEU# @ZF1PM8=QX]\.PPRM%J4=U+'MQ!;_/(Y;H%
MZFJ=EX)T/1=-%[JJ?VA<V\?FSW5VQ?)499L'@5Q7A&QO-/@N-?O[2&SO];V-
MI^I>4&CMU<J(XS&/N9! ]Z /3-.U6X"PMK1@L9[R3%M:%P7 ]">[?3I6R[A%
MW,0 !DDG@5Y/KOAI],\6>$KV\OKC4M8N]87?,_"1Q(C,51>BCH?PKI/%5T?$
M>KQ^#+*5U#@3ZI/$<&&#.0F>S.<#Z9- '.>)?B4]Y%=#2))[72;=Q#/J:Q9>
M20Y CA!X[?>JSX>U8PV2P^$_"MU<7#HK37U^?+#LW)+.>6Z]O2LS5- UG1M5
M\,^&HA!?Z1%>M>6D*824I I;8^>& ++SWKU72[[^T+-9OLL]L>C13IM93CIB
M@#$M]*\3W\2_VGK45L"26CL8L'!QQN//'/-=2N<<T"EH *0L%!)(  S0>E<0
MEI=>--8O9;NZFA\/6<S6L-I"Y0W;J<2/(PYVALJ%'7!)H U-0\<^'M.NA:2:
M@DUTQPL%N#*Y/887/6N4UN!O%4RW.G^"+LW462M[<2_8G/MG(8\^HKOM,T+2
M]&B\O3=/MK5<8/DQ!2>G4]3T%: % 'DUGX8^)ZHK1>(+:S5VW/%/)Y[)VP#M
MK3\/Z-)#\3IC=R1RW%AI*/+(B[1)/.Y#R!>V5A /US7H]9L6CP1:_=:NC,)[
MFWCMY!VPC,5/U^<T 8WQ*>6/X9^(C"K,_P!@D!"_W2,,?RS6DEG;WOAFWM;D
M[89+>)20<%3@8(]P<$5HWEG#?64UG<H)()XVBE1NC*PP1^1KEM(\(ZI UK:Z
MOK(OM-T]@;2$1[6DP?D,Q.=Q7 QC'(R<T )XYLM4VZ1K.BVC7E_I=YYHMPP'
MF(Z-&XY_WA^M7/!7AR70=(9]0D%QK%Z_VC4+CKOD/8'^ZHX%=)M]>:4#% ',
M^)]#U2\U32-7T:6V%[IS3+Y5UD(\<J@-R,D$;5Q^-7]%M-8A\R?6+^.>:0#]
MS!'MCBY/0GENH&3CITK8HH **** $/2JMG86UB]RUO'L^TS&>7YB<N0 3STZ
?#I110!;HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g57431g1210025456111.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g57431g1210025456111.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  8 -\# 2(  A$! Q$!_\0
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7*W>N)=VD<801?90AX& <@UT-%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
